An Exton gene-therapy maker, after high hopes, sold at modest price – The Philadelphia Inquirer

Fibrocell in April had signed a deal with Castle Creek, a unit of Chicago-based Paragon Biosciences, to pay Fibrocell and partner Intrexon Corp., of Germantown, Md., up to $135 million for licensing, developing, and producing Fibrocells gene-therapy candidate FCX-007, for the treatment of recessive dystrophic epidermolysis bullosa, a genetic condition leading to sores, scarring, skin cancer, and vision loss for up to 2,500 Americans. There is no cure.

More:

An Exton gene-therapy maker, after high hopes, sold at modest price - The Philadelphia Inquirer

Related Post

Comments are closed.